Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A Novel Drug Induces DEPTOR Degradation in Myeloma Cells with Resulting Tumor Cytotoxicity.

Vega MI, Shi Y, Frost P, Huerta-Yepez S, Antonio-Andres G, Hernandez-Pando R, Lee J, Jung ME, Gera JF, Lichtenstein A.

Mol Cancer Ther. 2019 Aug 8. pii: molcanther.0115.2019. doi: 10.1158/1535-7163.MCT-19-0115. [Epub ahead of print]

PMID:
31395691
2.

A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets.

Weisbart RH, Gera JF, Chan G, Hansen JE, Li E, Cloninger C, Levine AJ, Nishimura RN.

Mol Cancer Ther. 2012 Oct;11(10):2169-73. doi: 10.1158/1535-7163.MCT-12-0476-T. Epub 2012 Aug 3.

3.

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS.

Cancer Discov. 2011 Nov;1(6):524-38. doi: 10.1158/2159-8290.CD-11-0124. Epub 2011 Sep 13.

4.

IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1.

Shi Y, Frost PJ, Hoang BQ, Benavides A, Sharma S, Gera JF, Lichtenstein AK.

Cancer Res. 2008 Dec 15;68(24):10215-22. doi: 10.1158/0008-5472.CAN-08-1066.

5.

Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling.

Marderosian M, Sharma A, Funk AP, Vartanian R, Masri J, Jo OD, Gera JF.

Oncogene. 2006 Oct 12;25(47):6277-90. Epub 2006 May 15.

PMID:
16702957
6.

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK.

J Biol Chem. 2004 Jan 23;279(4):2737-46. Epub 2003 Oct 23.

7.

Array-based methods for identifying protein-protein and protein-nucleic acid interactions.

Gera JF, Hazbun TR, Fields S.

Methods Enzymol. 2002;350:499-512. No abstract available.

PMID:
12073332
8.

Towards an understanding of complex protein networks.

Tucker CL, Gera JF, Uetz P.

Trends Cell Biol. 2001 Mar;11(3):102-6. Review.

PMID:
11306254
10.

Inhibition of DNA repair with aphidicolin enhances sensitivity of targets to tumor necrosis factor.

Gera JF, Fady C, Gardner A, Jacoby FJ, Briskin KB, Lichtenstein A.

J Immunol. 1993 Oct 1;151(7):3746-57.

PMID:
8376804
12.
13.

Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis.

Lichtenstein A, Fady C, Gera JF, Gardner A, Chazin VR, Kelley D, Berenson J.

Cell Immunol. 1992 Apr 15;141(1):219-32.

PMID:
1348216
15.

Human neutrophil peptide defensins induce single strand DNA breaks in target cells.

Gera JF, Lichtenstein A.

Cell Immunol. 1991 Nov;138(1):108-20.

PMID:
1913832
16.

Inhibitors of ADP-ribose polymerase decrease the resistance of HER2/neu-expressing cancer cells to the cytotoxic effects of tumor necrosis factor.

Lichtenstein A, Gera JF, Andrews J, Berenson J, Ware CF.

J Immunol. 1991 Mar 15;146(6):2052-8.

PMID:
1672341
17.

Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.

Lichtenstein A, Berenson J, Gera JF, Waldburger K, Martinez-Maza O, Berek JS.

Cancer Res. 1990 Nov 15;50(22):7364-70.

Supplemental Content

Support Center